Pfizer Inc. (PFE)
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025)
Shares of Pfizer ( NYSE: PFE ) lost 9.90% over the past month after gaining 10.02% the month prior.
Pfizer raises 2025 profit forecast for second time in a row
Pfizer lifted its full-year profit forecast for the second time in a row on Tuesday, buoyed by strong demand for its blockbuster heart treatment and blood thinner.
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.
Heard on the Street: Novo Nordisk and Pfizer are showing some desperation in their gloves-off fight for the obesity-drug assets of Metsera
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.
Is It Time to Dump Your Shares of Pfizer?
After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon.
Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera
The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.
Pfizer sues Metsera, Novo Nordisk over breach of merger deal
Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.
Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?
Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.
How Pfizer Stock Can Rebound
Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer.
What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings
Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.
Denmark's Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.
Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera
Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors.
